



# EstroFree<sup>100</sup><sup>®</sup>

*CYNANCHUM WILFORDII, PHLOMIS UMBROSA  
& ANGELICA GIGAS*


## MENOPAUSE, A BOTHERSOME CONDITION

- The typical age of menopause is between 40 and 61 with an average of 51 years old.
- During menopause, women may suffer from several **bothersome symptoms that seriously impact their quality of life.**  
Percentage of women affected by menopausal symptoms:



## MENOPAUSE, A UNIVERSAL CONCERN

- In Europe, there are **more than 72 million women** of menopausal age.
- **70% of women remain untreated** because of unsatisfying treatments.



## WOMEN'S EXPECTATIONS

The quality of life and intimate life are so adversely affected by menopausal symptoms such as hot flashes and vaginal dryness, that **concerned women need a highly effective, safe & natural solution** to cope with this condition.

## ESTROFREE-100<sup>®</sup>, THE NOVEL NON-ESTROGENIC & SAFE SOLUTION FOR MENOPAUSE

### NOVEL & PATENTED

EstroFree-100<sup>®</sup> is a completely **"New-to-market"** patented solution for menopausal women.

### NATURAL

EstroFree-100<sup>®</sup> is made of a standardized blend of 3 botanical extracts:

***Cynanchum wilfordii*, *Phlomis umbrosa* and *Angelica gigas*.**

These plants have been used for more than 400 years in Asian folk medicine.

### NON-ESTROGENIC & SAFE

EstroFree-100<sup>®</sup> has been shown to lack of affinity to both alpha- and beta-estrogen receptors *in vitro*, thus confirming the **non-estrogenic mode of action.**

EstroFree-100<sup>®</sup> does not present any side effect.

### CLINICALLY PROVEN

EstroFree-100<sup>®</sup> has been proven to significantly relieve menopausal symptoms in 3 randomized, double-blind, placebo-controlled clinical studies on over 200 women.


Mode of action | See  
Clinical studies | next page



## ESTROFREE-100®, THE ESTROGEN-FREE MODE OF ACTION

Extensive GLP toxicity studies have shown that **EstroFree-100®** is **unable to induce any hormonal activity or hormonal effect**.


Dose-dependent curve of estradiol and EstroFree-100® to alpha- and beta-estrogen receptors (ER)



## ESTROFREE-100®, THE CLINICALLY PROVEN SOLUTION

- 2005: 12-month, randomized, double-blind, placebo-controlled study. N=42 peri-menopausal women.
- 2011: 12-week, randomized, double-blind, placebo-controlled study. N=61 pre-, peri- & post-menopausal women.
- 2014: 12-week, multicenter, randomized, double-blind, placebo-controlled study. N=96 peri-menopausal women.

### COMPARISON OF MENOPAUSAL SYMPTOMS SCORES AFTER 12 WEEKS OF ESTROFREE-100® SUPPLEMENTATION (N=61)<sup>1</sup>



\* p<0.01 vs placebo \*\* p<0.05 vs placebo

<sup>1</sup> Chang et al. The Effect of Herbal Extract (EstroFree-100) on Pre-, Peri- and Post-Menopausal Women: A Randomized Double-blind, Placebo-controlled Study. *Phytotherapy Research* (2011)

**ALL MENOPAUSAL SYMPTOMS WERE SIGNIFICANTLY DECREASED IN WOMEN TAKING ESTROFREE-100® VS THE PLACEBO GROUP. THE KUPPERMAN MENOPAUSAL INDEX WAS IMPROVED BY 54% AFTER 6 WEEKS & 62% AFTER 12 WEEKS OF SUPPLEMENTATION.**

## TECHNICAL INFORMATION

- **Actives:** Patented standardized blend of 3 botanical extracts (*Cynanchum wilfordii*, *Phlomis umbrosa* and *Angelica gigas*)
- **Regulatory:** Food supplement
- **Presentation:** 60 coated tablets in plastic vial
- **Posology:** 1 tablet twice daily
- **Quality:** Manufactured in France following GMP standards

ESTRO\_CPH\_MAIL\_1018\_00

**INNOVATIVE & GLOBAL SOLUTION  
NATURAL & NON-ESTROGENIC - CLINICALLY PROVEN  
PATENTED STANDARDIZED EXTRACT**



All product related information (including but not limited to therapeutic indications), trademarks, brand names and trade-dress provided herein are used by STRAGEN mainly for B2B purposes, and are the sole property of STRAGEN or under exclusive license. Any use of trademarks or brand names or trade-dress stated herein requires a prior written agreement from STRAGEN.

